Advanced search
Publication Cover
Clinical and Experimental Hypertension Volume 41, 2019 - Issue 7
Submit an article Journal homepage
159
Views
3
CrossRef citations to date
0
Altmetric
Articles

Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring

Kazuo KobayashiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, JapanCorrespondence[email protected]
,
Masao ToyodaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan;Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara, Japan
,
Moritsugu KimuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan;Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara, Japan
,
Nobuo HatoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Takayuki FurukiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Hiroyuki SakaiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Masahiro TakihataCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Tomoya UmezonoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Shun ItoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Daisuke SuzukiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Hiroshi TakedaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Akira KanamoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Hisakazu DegawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Hareaki YamamotoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Hideo MachimuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Atsuko MokuboCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Keiichi ChinCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Mitsuo ObanaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Toshimasa HishikiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Kouta AoyamaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Shinichi NakajimaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Shinichi UmezawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Hidetoshi ShimuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Togo AoyamaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
,
Kazuyoshi SatoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
&
Masaaki MiyakawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan
 show all
Pages 637-644 | Received 11 Jul 2018, Accepted 23 Sep 2018, Published online: 29 Oct 2018

References

  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. EMPA-REG OUTCOME investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(222):2117–28. doi:10.1056/NEJMoa1504720.
  • Neal B, Perkovic V, Kw M, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Dr M. CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. doi:10.1056/NEJMoa1611925.
  • Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ. EMPA-REG OUTCOME® Investigators. Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease- results from EMPA-REG OUTCOME®. Circ J. 2017;81(2):227–34. doi:10.1253/circj.CJ-16-1148.
  • Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, et al. Japanese society of hypertension committee for guidelines for the management of hypertension. The japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;3(4) 7:253–390.
  • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;392(Suppl 1):S1–266.
  • Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92. doi:10.1053/j.ajkd.2008.12.034.
  • Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93. doi:10.1056/NEJMicm020037.
  • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91. doi:10.1056/NEJMoa0706245.
  • Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinol. 2017;5(12):951–64. doi:10.1016/S2213-8587(17)30327-3.
  • Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;2(7) 9:1253–69. doi:10.1097/HJH.0b013e3283469976.
  • Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Ohira T, Tanigawa T, Yamagishi K, Nakamura M, et al. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol. 2008;52(1):71–79. doi:10.1016/j.jacc.2008.02.075.
  • Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75. doi:10.1016/j.jash.2014.01.007.
  • List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–57. doi:10.2337/dc08-1863.
  • DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26. doi:10.1038/nrneph.2016.170.
  • Kobayashi K, Sato K, Hatori N, Miyakawa M. A questionnaire survey of general practitioners in Japan’s kanagawa prefecture for the Japanese society of hypertension guidelines for the management of hypertension 2014. Clin Exp Hypertens. 2017;39(8):705–10. doi:10.1080/10641963.2017.1313852.
  • Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, Asayama K, Björklund-Bodegård K, Ohkubo T, Jeppesen J, et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension. 2013;61(5):964–71. doi:10.1161/HYPERTENSIONAHA.111.00289.
  • Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193–98. doi:10.1097/HJH.0b013e3282ef6185.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.